A case of <scp>MDS</scp>/<scp>MPN</scp> overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage-Reference-Cited by-同舟云学术

A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage

Published:2023-05-29 Issue:6 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Cherniawsky Hannah¹,Razavi Habib Moshref²³^ORCID

Affiliation:

1. Division of Haematology, Department of Medicine University of British Columbia Vancouver British Columbia Canada

2. Division of Hematopathology and Transfusion Medicine, Fraser Health Authority University of British Columbia Vancouver British Columbia Canada

3. Department of Pathology and Laboratory Medicine University of British Columbia Vancouver British Columbia Canada

Abstract

Key Clinical MessageNo formal treatment guidelines for MDS/MPN‐RS‐T exist. With salient features such as anemia and thrombocytosis, management is individualized and aims to address anemia, thrombosis, and in some cases acquired von Willebrand's disease.AbstractMyelodysplastic/myeloproliferative overlap syndrome with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) is a rare myeloid neoplasm showing myelodysplastic and myeloproliferative features. With extremely raised platelets, possibility of acquired von Willebrand and risk of hemorrhage is increased. With this quandary in mind, a descriptive case and a brief discussion of available treatments ensues.

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.7409

Reference28 articles.

1. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

2. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations

3. Myelodysplastic syndromes with ring sideroblasts ( MDS‐RS ) and MDS /myeloproliferative neoplasm with RS and thrombocytosis ( MDS/MPN‐RS‐T ) – “ 2021 update on diagnosis, risk‐stratification, and management”